PN-943 / Studies

Synthetic analog

PN-943 studies and research data

PepBank has 1 PN-943 study with results. It gave PN-943, with 13 results, grouped by what the studies measured. In each group, results from studies in people come first. Data as of 2026-10-30.

Searches 13 results and 3 papers. Newer studies from Europe PMC

Results in people

100% of 13 results

Results in animals

0% of 13 results

Results in lab cells

0% of 13 results

From computer models

0% of 13 results

The molecule

PN-943 identity

Identifiers, parent molecule, targets and development stage, from curated data.

PN-943 is an orally stable, gastrointestinal-restricted cyclic peptide antagonist of alpha4beta7 integrin. It is a structural analog of PTG-100. Human studies investigated oral formulations and ulcerative colitis.

Kind: Synthetic analog
Parent: Analog of PTG-100The primary paper identifies PN-943 as a structural analog of PTG-100. No residue alignment was established.
Development: Phase 2Protagonist TherapeuticsPN-943 reached phase 2. In its 2024 annual report, filed in February 2025, Protagonist declined further internal clinical development and manufacturing resources. This dated statement does not establish current licensing activity. Both listed trials tested participants. The ANZCTR target count differs from the actual count reported in the paper. Source (opens in a new tab)

Targets

Molecular targets with action and evidence source
Target	Action	Evidence
ITGA4ITGA4P13612 (opens in a new tab)	Antagonist	Primary pharmacology paper and reviewed human UniProt entrySource (opens in a new tab)
ITGB7ITGB7P26010 (opens in a new tab)	Antagonist	Primary pharmacology paper and reviewed human UniProt entrySource (opens in a new tab)

Sequence and structure

Residues, differences from the parent, calculated properties and 3D structure. Source values and calculated values are shown separately.

Sequence

Sequence not disclosed

The primary paper identifies PN-943 as a small, disulfide-containing cyclic peptide and a structural analog of PTG-100. Complete sequence, stereochemistry, bond positions, termini and chemical properties remain unverified. Empty bond and modification arrays do not establish their absence.

Parent: PTG-100

No sequence is listed for the parent, so no alignment is shown.The primary paper identifies PN-943 as a structural analog of PTG-100. No residue alignment was established.

Properties

From identity sources

No formula or molecular weight is listed for PN-943.

Calculated from the sequence

No sequence is listed, so nothing can be calculated.

Net charge by pH

No charge curve

No sequence is listed for this peptide.

Composition

No sequence is listed for this peptide.

3D structure

No 3D structure

No experimental structure (PDB) and no UniProt entry for an AlphaFold model are listed for this peptide. Synthetic peptides often have neither. The sequence view above is the reference.

Results by area

PN-943 results by year and outcome

Counts are exact and come from studies that gave the peptide.

Studies by year

1 of 3 studies has results (33%), published 2021. Top row: every study. Bottom row: studies with results about PN-943, by class. The rows use different scales.

Studies
Human
Animal
Lab
Computer model
Natural levels, tool or combination only

Studies3 in all, 2021 to 2024

Studies with results1 in all, 2021

Retracted studies are left out. A study with results in two classes counts in both.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

What the studies measured

People first in each area, then animals, then lab cells. Counts are exact and come from studies that gave the peptide.

PN-943 studies on blood levels and clearance

9 results · people 9 · animals 0 · lab 0

Top 3 of 9 results

In healthy volunteers, little PN‑943 reached the general circulation.Clinical pharmacology in drug development, 2021
In healthy volunteers, PN‑943 blood exposure increased approximately in proportion to dose.Clinical pharmacology in drug development, 2021
In healthy volunteers, little PN‑943 accumulated with daily dosing.Clinical pharmacology in drug development, 2021

PN-943 studies on receptors and cell signals

3 results · people 3 · animals 0 · lab 0

3 results

In healthy volunteers, PN‑943 occupied more blood receptors as the dose increased.Clinical pharmacology in drug development, 2021
In healthy volunteers, PN‑943 reduced blood receptor expression as the dose increased.Clinical pharmacology in drug development, 2021
In healthy volunteers, twice-daily PN‑943 maintained receptor occupancy.Clinical pharmacology in drug development, 2021

PN-943 studies on side effects

1 result · people 1 · animals 0 · lab 0

1 result

In healthy volunteers, nobody stopped PN‑943 because of treatment-emergent side effects.Clinical pharmacology in drug development, 2021

Trials and papers

PN-943 trials

Registered trials that test the peptide, with phase, status and dates. A dot marks trials with posted results.

StatusPhase

1 trial match. Highest phase first. Data from ClinicalTrials.gov.

Trials on this page (1 of 1)

1 trial · 1 completed

Completed
Ongoing
Not yet recruiting
Stopped
Estimated dates (est.)
Results posted

20202021202220232024

Ph 2
PN-943 in Adults With Moderate to Severe Active Ulcerative Colitis (UC)
NCT04504383
5 Aug 2020 to 16 Feb 2023

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 2NCT04504383

PN-943 in Adults With Moderate to Severe Active Ulcerative Colitis (UC)

Protagonist Therapeutics, Inc.n = 1695 Aug 2020 to 16 Feb 2023

Ulcerative Colitis Chronic Moderate · Ulcerative Colitis Chronic Severe

Trial page ClinicalTrials.govUpdated 25 Apr 2023

Papers

Studies on this peptide. Some have results. The others have none yet.

Sort

Design

3 studies match. Retracted studies are left out.

Showing 3 of 3 studiesquery qry_a5d87f124a503bba905d4428

Studies with results

1 study

Non-randomized trial · 2021

13 results

Single- and Multiple-Dose Pharmacokinetics and Pharmacodynamics of PN-943, a Gastrointestinal-Restricted Oral Peptide Antagonist of α4β7, in Healthy Volunteers.

Modi et al. 2021Clinical pharmacology in drug developmentcited by 14

PMID 33942566PMC8597174DOI 10.1002/cpdd.946PUB-33942566

Free to read · publisher termsCC BY-NC-ND13 results where PN-943 was given

Read at source See results (13)

More studies

2 studies

PubMed tag: review-article, Review · 2021

Anti-Integrins for the Treatment of Inflammatory Bowel Disease: Current Evidence and Perspectives.

Gubatan et al. 2021Clinical and experimental gastroenterologycited by 75

PMID 34466013PMC8402953DOI 10.2147/ceg.s293272PUB-34466013

Free to read · publisher termsCC BY-NC

Read at source

PubMed tag: review-article, Review · 2024

[Old and New Biologics and Small Molecules in Inflammatory Bowel Disease: Anti Integrins].

Kim et al. 2024The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chicited by 2

PMID 39176460PMC12285414DOI 10.4166/kjg.2024.070PUB-39176460

Free to read · publisher termsCC BY-NC

Read at source

Newer studies

PepBank reads each paper before it shows the results. This search looks in Europe PMC for newer papers that PepBank has not read yet.

PN-943 studies: 1 paper with results

Page 1 of 1

Single- and Multiple-Dose Pharmacokinetics and Pharmacodynamics of PN-943, a Gastrointestinal-Restricted Oral Peptide Antagonist of α4β7, in Healthy Volunteers.
Modi NB · Clinical pharmacology in drug development · 2021
Non-randomized trial · 13 results

Status and safety

Regulatory and safety

Approval and sport status, and the safety outcomes reported in study results. Laws and labels change, so check the regulator for the current status.

Regulatory status by jurisdiction, with date and source
Jurisdiction	Body	Status	As of	Source
US	FDA	The sponsor describes PN-943 as investigational in its 2024 annual report filed in February 2025. Current FDA approval was not established.	27 Oct 2026	sec.gov (opens in a new tab)
EU	EMA	The European trial record states that PN-943 has no marketing authorisation for that trial. Current central or national marketing approval was not established.	27 Oct 2026	clinicaltrialsregister.eu (opens in a new tab)
Sport	WADA	Status unknown PN-943 is not named in the 2026 list.	2026 List	wada-ama.org (opens in a new tab)
Canada	Note	Health Canada records trial authorisation on March 24, 2020, for protocol PN-943-03. Trial authorisation does not establish marketing approval. Current national marketing approval was not established.	27 Oct 2026	clinical-trials-search.canada.ca (opens in a new tab)

Safety outcomes

1 safety result for PN-943.

Human evidence· 1

In healthy volunteers, no subjects discontinued PN‑943 because of treatment-emergent adverse events.
Non-randomized trialn not reported

Doses studied

The doses that these studies used. They are not recommendations.

No dose was reported in the study results.

PepBank is a research reference. Talk to a doctor before you use any peptide.

Data

Data and API

Data version, change history and code for this peptide.

Data version 30856030 Oct 2026

Peptide

Peptide id: PEP-000165
Peptide version: 2
Peptide hash: 7aa4fd2f54d4963f…
Data version: 308560

Latest changes

27 Oct 2026UpdatedData version 287308
27 Oct 2026CreatedData version 256761

For developers

curl -s https://pepbank.io/v1/briefs/pn-943

Evidence summary for PN-943: counts by class, key results with sources, notices, data version.

Peptide as JSON Evidence summary as JSON

Outcome group	Human	Animal	Lab	Computer model	Total
PharmacokineticsPharmacology	Human: 9 results from 1 study: 2 increase, 2 decrease, 1 no significant change, 4 not reported. Strongest design: Non-randomized trial	No results	No results	No results	9
Receptor activity and mechanismPharmacology	Human: 3 results from 1 study: 1 increase, 1 decrease, 1 not reported. Strongest design: Non-randomized trial	No results	No results	No results	3
Adverse eventsWhole body	Human: 1 result from 1 study: 1 not reported. Strongest design: Non-randomized trial	No results	No results	No results	1

Outcome group	Human	Animal	Lab	Computer model	Total
PharmacokineticsPharmacology	Human: 9 results from 1 study: 2 increase, 2 decrease, 1 no significant change, 4 not reported. Strongest design: Non-randomized trial	No results	No results	No results	9
Receptor activity and mechanismPharmacology	Human: 3 results from 1 study: 1 increase, 1 decrease, 1 not reported. Strongest design: Non-randomized trial	No results	No results	No results	3
Adverse eventsWhole body	Human: 1 result from 1 study: 1 not reported. Strongest design: Non-randomized trial	No results	No results	No results	1

PN-943 studies and research data

PN-943 identity

Targets

Sequence and structure

Sequence

Parent: PTG-100

Properties

Net charge by pH

Composition

3D structure

PN-943 results by year and outcome

What the studies measured

PN-943 studies on blood levels and clearance

PN-943 studies on receptors and cell signals

PN-943 studies on side effects

PN-943 trials

PN-943 in Adults With Moderate to Severe Active Ulcerative Colitis (UC)

Papers

Studies with results

Single- and Multiple-Dose Pharmacokinetics and Pharmacodynamics of PN-943, a Gastrointestinal-Restricted Oral Peptide Antagonist of α4β7, in Healthy Volunteers.

More studies

Anti-Integrins for the Treatment of Inflammatory Bowel Disease: Current Evidence and Perspectives.

[Old and New Biologics and Small Molecules in Inflammatory Bowel Disease: Anti Integrins].

Newer studies

PN-943 studies: 1 paper with results

Regulatory and safety

Human evidence· 1

Doses studied

Data and API

Peptide

Latest changes

For developers

Related peptides

PN-943 results by year and outcome

PN-943 studies on blood levels and clearance

PN-943 studies on receptors and cell signals

PN-943 studies on side effects

PN-943 trials

PN-943 in Adults With Moderate to Severe Active Ulcerative Colitis (UC)

Papers

Studies with results

Single- and Multiple-Dose Pharmacokinetics and Pharmacodynamics of PN-943, a Gastrointestinal-Restricted Oral Peptide Antagonist of α4β7, in Healthy Volunteers.

More studies

Anti-Integrins for the Treatment of Inflammatory Bowel Disease: Current Evidence and Perspectives.

[Old and New Biologics and Small Molecules in Inflammatory Bowel Disease: Anti Integrins].

PN-943 studies: 1 paper with results

Regulatory and safety

Human evidence· 1

Doses studied

Data and API

Peptide

Latest changes

For developers